A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment

Exclusion Criteria

• •All participants (including participants with T2DM)
• •Are currently enrolled in, discontinued within the last 30 days from a clinical trial involving use of an investigational drug or device other than the study drug, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
• •Have known allergies to LY2189265 or related compounds
• •Have previously completed or withdrawn from this study or any other study investigating LY2189265
• •Have a current, functioning organ transplant
• •Show evidence of significant active, uncontrolled, endocrine or autoimmune abnormalities (such as, thyroid disease or pernicious anemia) as judged by the screening physician
• •Have shown febrile illness within 3 days prior to screening
• •Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
• •Regularly use known drugs of abuse and/or show positive findings on urinary drug screening that are not otherwise explained by permitted concomitant medications
• •Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies
• •Are women with a positive pregnancy test or women who are lactating
• •Have donated blood of more than 500 milliliters (mL) within the last month prior to screening
• •Have an average weekly alcohol intake that exceeds 21 units per week (men) and 14 units per week (women) (1 unit = 12 ounces \[oz\] or 360 mL of beer, 5 oz or 150 mL of wine, or 1.5 oz or 45 mL of distilled spirits)
• •Are unwilling to stop alcohol consumption for the duration of the study (from screening until the follow-up visit)
• •Are participants who smoke more than 10 cigarettes per day, are unwilling to refrain from smoking on the day of LY2189265 administration, or are unable to abide by clinical research unit (CRU) restrictions on other inpatient days
• •Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder, (for example relevant esophageal reflux or gall bladder disease, or any gastrointestinal disease which impacts gastric emptying \[such as, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy\] or could be aggravated by glucagon like peptide \[GLP\] analogs). Participants with mild hypertension and dyslipidemia, and participants who had cholecystolithiasis (removal of gall stones) and/or cholecystectomy (removal of gall bladder) in the past, with no further sequelae, may be included in the study at the discretion of the screening physician.
• •Are participants deemed to be unsuitable by the investigator for any reason.
• •Control participants:
• •Have a history or presence of cardiovascular (such as, myocardial infarction, cerebrovascular accident, venous thromboembolism), respiratory, renal, endocrine (with exception of participants with T2DM), hematological, neurological disorders, cancer, hepatic (including Gilbert's disease), or dermatological disorders or diseases capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
• •Show evidence of significant active neuropsychiatric disease
• •Have creatinine clearance less than 80 milliliters per minute (mL/min) (as calculated by the Cockcroft-Gault equation)
• •Show evidence of hepatitis B and/or positive hepatitis B surface antigen
• •Show evidence of hepatitis C and/or positive hepatitis C antibody
• •Intend to use:
• •* Over-the-counter medication (including herbal remedies/health supplements) within 7 days prior to dosing
• •* Prescription medication within 14 days prior to dosing participants with mild, moderate, and severe hepatic impairment
• •Show evidence of any significant active disease other than that responsible for or associated with hepatic impairment. Participants with hypertension and hyperlipidemia may be permitted at the investigator's discretion.
• •Show, in the opinion of the investigator, evidence of significant neuropsychiatric disease other than Grade 1 hepatic encephalopathy
• •Show evidence of spontaneous bacterial peritonitis within 6 months of dosing.
• •Show evidence of severe hyponatremia (Sodium \[Na\] \<120 millimoles per liter \[mmol/L\])
• •Show presence of hepatocellular carcinoma
• •Have a portal shunt
• •Show evidence of severe ascites
• •Have hemoglobin \<9.0 grams per deciliter (g/dL)
• •Have platelet count \<40 x 10\^9 cells per liter (cells/L)
• •Have total serum bilirubin \>15 milligrams per deciliter (mg/dL)
• •Use medication known to interfere with hepatic metabolism (that is, barbiturates, phenothiazines) or known to alter other major organs or systems
• •Mild, Hepatic Impaired Participants (Child-Pugh A)
• •Show evidence of active renal disease with creatinine clearance \<70 mL/min calculated by the Cockcroft-Gault equation.
• •Moderate and Severe Hepatic Impaired Subjects (Child-Pugh B and C)
• •Show evidence of hepatorenal syndrome as shown by creatinine clearance \<50 mL/min calculated by the Cockcroft-Gault equation.